CONTINUING EDUCATION

Objectives as of May 12, 2026.

To date, conference educational objectives are to recognize, discuss and debate the following:

Allergy and Immunology

• Describe the adrenal gland's function and importance.
• Explain adrenal gland insufficiency, its causes and how it is evaluated.
• Understand glucocorticoid withdrawal syndrome.
• Explain the allergy and immune system relationship.
• Review allergy diagnostic tests and tools.
• Describe common allergic reactions and their severity.
• Identify clinical characteristics of allergy patients that indicate allergy immunotherapy.
• Review short-term and long-term efficacy and safety of allergy immunotherapy.
• Discuss new forms of allergy immunotherapy and the potential for alternative treatments.
• Understand the role of Type 2 inflammation in the pathophysiology of common allergic conditions.
• Identify the markers of Type 2 inflammation in a patient.
• Understand the implications for therapy and consequences of untreated Type 2 inflammation disease.
• Explain the evolution of Mast Cell Activation Syndrome (MCAS).
• Outline the criteria that supports a MCAS diagnosis.
• Describe the origins of how MCAS presumptive diagnosis by non-allergists developed.
• Learn how to enhance validated diagnostic criteria to minimize the risk of missing MCAS cases.
• Identify clinical “red flags” for inborn errors of immunity beyond recurrent infections, including autoimmunity, inflammation and malignancy. 
• Apply a practical, stepwise approach to the initial evaluation of suspected immune dysregulation in adults. 
• Distinguish when referral, advanced testing, or genetic evaluation is indicated in complex patients.

Food Allergy

• Evaluation and management with relationship-centered communication - objectives PENDING.
• Describe the U.S. Food & Drug Administration (FDA) regulatory perspective in the approach to developing food allergy therapy.
• Outline current evidence that supports the use of selected food allergy therapies.
• Evaluate the risks, benefits and trade-offs of current and future food allergy therapy options..

Asthma and Respiratory Disease

• Recognize analgesic medications that must be avoided by patients with aspirin-exacerbated respiratory disease (AERD).
• Describe the therapeutic utility of FDA-approved biologic agents and aspirin desensitization, and the patients who are appropriate candidates for these interventions.
• Outline unmet needs in managing AERD.
• Review the epidemiology and clinical burden of asthma in the United States and how disease patterns have evolved over the past several decades.
• Compare historical and current asthma treatment strategies, including the transition from generalized therapies to targeted biologic and precision-based management.
• Discuss emerging asthma therapeutics, including novel biologics, RNA-based therapies, and genetic approaches that may shape the future of asthma care .
• Describe at least two diagnostic therapy probes or techniques used by speech-language pathology therapists and clinicians to identify chronic cough.
• Outline the three most common causes of common cough.
• Identify five medical team members often involved in diagnosing chronic cough.
• Learn criteria to diagnose myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID primarily in patients presenting with complex allergy and immunology symptoms.
• Recognize the clinical relevance of co-occurring conditions (such as autoimmune dysfunction and mast cell activation syndrome) when assessing and managing patients with ME/CFS and Long-COVID.

Skin Deep

• Atopic dermatitis challenges and relationship-centered communication - objectives PENDING.
• Describe an evidence-based and cost-effective approach to diagnosing and managing patients with chronic urticaria.
• Recognize patients with chronic inducible urticaria syndromes.
• Identify patients with refractory chronic urticaria.

Social and Environmental

• Review societal movements to resist / distrust medical therapies and vaccines for infectious disease.
• Relate historic resistance movements to preventable deaths and disasters from infectious disease.
• Discuss ways medical leaders can eliminate or mitigate resistance-based deaths and disasters.
• Describe the parallels between the Digital Age and the emerging Biological Age, including how artificial intelligence is accelerating drug discovery, precision medicine, and biologic innovation.
• Review the evolving therapeutic landscape in allergy, asthma, and immunology, including monoclonal antibodies, small molecules, RNA therapeutics, gene therapy, and CRISPR-based technologies.
• Discuss how AI-driven and programmable biologic therapies may transform the future management of allergic, inflammatory, and immunologic diseases, moving care from reactive treatment toward predictive and disease-modifying interventions .
• Identify work exposure conditions that increase risk for occupational respiratory and skin disorders.
  Evaluate when asthma and contact dermatitis are work-related.
• Understand how to manage occupational asthma and dermatitis.